Qisi Zhang, Cyrille S. Kounde, Milon Mondal, Jake L. Greenfield, Jennifer R. Baker, Sergei Kotelnikov, Mikhail Ignatov, Christopher P. Tinworth, Leran Zhang, Daniel Conole, Elena De Vita, Dima Kozakov, Adam McCluskey, John D. Harling, Matthew J. Fuchter and Edward W. Tate

Chem. Commun., 2022, 58, 10933
DOI: 10.1039/D2CC03092F

Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation

Yu Chen, Ira Tandon, William Heelan, Yixin Wang, Weiping Tang and Quanyin Hu

Chem. Soc. Rev., 2022, 51, 5330
DOI: 10.1039/D1CS00762A

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

Claudia J. Diehl and Alessio Ciulli

Chem. Soc. Rev., 2022, 51, 8216
DOI: 10.1039/D2CS00387B

Chemistries of bifunctional PROTAC degraders

Chaoguo Cao, Ming He, Liguo Wang, Yuna He and Yu Rao

Chem. Soc. Rev., 2022, 51, 7066
DOI: 10.1039/D2CS00220E

PROTAC for agriculture: learning from human medicine to generate new biotechnological weed control solutions

Ramon G. Leon and Diane C. Bassham

Pest Management Science, 2024, 80, 262
DOI: 10.1002/ps.7741

Recent Advances in Optically Controlled PROTAC

Muzi Ouyang, Ying Feng, Hui Chen, Yanping Liu, Chunyan Tan and Ying Tan

Bioengineering, 2023, 10, 1368
DOI: 10.3390/bioengineering10121368

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Junhyeong Yim, Junyoung Park, Gabin Kim, Hyung Ho Lee, Jin Soo Chung, Ala Jo, Minseob Koh and Jongmin Park

ChemMedChem, 2024, 19
DOI: 10.1002/cmdc.202400326

Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras

Mei-Yu Lv, Da-Yong Hou, Shao-Wei Liu, Dong-Bing Cheng and Haoran Wang

ACS Nano, 2025, 19, 101
DOI: 10.1021/acsnano.4c11903

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Chao Wang, Yujing Zhang, Wujun Chen, Yudong Wu and Dongming Xing

Mol Cancer, 2024, 23
DOI: 10.1186/s12943-024-02024-9

Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2

Muhammed Shaheer, Ravi Singh and M. Elizabeth Sobhia

Journal of Biomolecular Structure and Dynamics, 2022, 40, 10905
DOI: 10.1080/07391102.2021.1953601

Photopharmacology-based small-molecule Proteolysis Targeting Chimeras: Optical Control of Protein Degradation

Wen Li, Reham M Elhassan, Hao Fang and Xuben Hou

Future Med. Chem., 2020, 12, 1991
DOI: 10.4155/fmc-2020-0210

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Ruolan Liu, Mei Yang, Edouard C. Nice, Huili Zhu and Canhua Huang

European Journal of Medicinal Chemistry, 2023, 257, 115447
DOI: 10.1016/j.ejmech.2023.115447

The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents

Bernat Coll-Martínez, Antonio Delgado and Bernat Crosas

Molecules, 2020, 25, 5956
DOI: 10.3390/molecules25245956

Photo-controllable biochemistry: Exploiting the photocages in phototherapeutic window

Hao Xiong, Yunjie Xu, Byungkook Kim, Hyeonji Rha, Bin Zhang, Mingle Li, Guang-Fu Yang and Jong Seung Kim

Chem, 2023, 9, 29
DOI: 10.1016/j.chempr.2022.11.007

Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs

Si-Han Zhang, Na Zeng, Jin-Zhou Xu, Chen-Qian Liu, Meng-Yao Xu, Jian-Xuan Sun, Ye An, Xing-Yu Zhong, Lin-Tao Miao, Shao-Gang Wang and Qi-Dong Xia

Biomedicine & Pharmacotherapy, 2024, 180, 117584
DOI: 10.1016/j.biopha.2024.117584

Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening

Federica Pedrucci, Claudia Pappalardo, Giovanni Marzaro, Nicola Ferri, Alberto Ferlin and Luca De Toni

IJMS, 2022, 23, 6630
DOI: 10.3390/ijms23126630

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Dhanusha A. Nalawansha and Craig M. Crews

Cell Chemical Biology, 2020, 27, 998
DOI: 10.1016/j.chembiol.2020.07.020

Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation

Hanqiao Xu, Nobumichi Ohoka, Takao Inoue, Hidetomo Yokoo and Yosuke Demizu

Bioorganic & Medicinal Chemistry Letters, 2024, 107, 129778
DOI: 10.1016/j.bmcl.2024.129778

Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy

Lixia Chen, Xinqiang Wan, Xiangxiang Shan, Wenzhang Zha and Rengen Fan

Mol Diagn Ther, 2022, 26, 283
DOI: 10.1007/s40291-022-00586-2

Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors

Heli Fan, Zhili Zhou, Dehao Yu, Jing Sun, Luo Wang, Yuanyuan Jia, Junyu Tian, Wenyi Mi and Huabing Sun

Bioorganic Chemistry, 2023, 140, 106793
DOI: 10.1016/j.bioorg.2023.106793

Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment

Baohua Xie, Bin Xu, Lilan Xin, Yizhou Wei, Xinyi Guo and Chune Dong

Bioorganic Chemistry, 2023, 137, 106590
DOI: 10.1016/j.bioorg.2023.106590

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology

Xuyang Zhao, Yifan Chen, Huang Su and Liqin Zhang

Interdisciplinary Medicine, 2023, 1
DOI: 10.1002/INMD.20230004

E3 ubiquitin ligases and deubiquitinases in colorectal cancer: Emerging molecular insights and therapeutic opportunities

Sunny Kumar, Malini Basu and Mrinal K. Ghosh

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2024, 1871, 119827
DOI: 10.1016/j.bbamcr.2024.119827

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

Carlotta Cecchini, Sara Pannilunghi, Sébastien Tardy and Leonardo Scapozza

Front. Chem., 2021, 9
DOI: 10.3389/fchem.2021.672267

Targeted Cancer Therapy Using Compounds Activated by Light

Petra Dunkel and Janez Ilaš

Cancers, 2021, 13, 3237
DOI: 10.3390/cancers13133237

Cancer Selective Target Degradation by Folate-Caged PROTACs

Jing Liu, He Chen, Yi Liu, Yudao Shen, Fanye Meng, H. Ümit Kaniskan, Jian Jin and Wenyi Wei

J. Am. Chem. Soc., 2021, 143, 7380
DOI: 10.1021/jacs.1c00451

De novo Semi‐Synthetic Platform for Monitoring Protein degradation in Live Cells

Mahdi Hasan, Deepanjan Panda, Guy Mann and Ashraf Brik

ChemBioChem, 2024, 25
DOI: 10.1002/cbic.202300731

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery

Shenxin Zeng, Hongjie Zhang, Zhengrong Shen and Wenhai Huang

Front. Chem., 2021, 9
DOI: 10.3389/fchem.2021.639176

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Siyu Chen, Jingliang Cui, Haiyan Chen, Bo Yu and Sihui Long

European Journal of Medicinal Chemistry, 2023, 262, 115911
DOI: 10.1016/j.ejmech.2023.115911

New Generation of PROTACs: Advancement in Light‐Responsive and Self‐Assembled PROTACs

Namrata Sapkota, Qi Xing and Jin Geng

ChemistrySelect, 2024, 9
DOI: 10.1002/slct.202403333

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

Ming He, Wenxing Lv and Yu Rao

Front. Cell Dev. Biol., 2021, 9
DOI: 10.3389/fcell.2021.685106

Controlling PROTACs with Light

Shreya Verma and Debasish Manna

ChemMedChem, 2020, 15, 1258
DOI: 10.1002/cmdc.202000249

Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation

Jiachan Lin, Zirui Chen, Dan Zhang, Nan Zhang, Hongzhong Chen and Dong‐Sheng Guo

Macromol. Rapid Commun., 2025, 46
DOI: 10.1002/marc.202401051

Clip Chemistry: Diverse (Bio)(macro)molecular and Material Function through Breaking Covalent Bonds

Peyton Shieh, Megan R. Hill, Wenxu Zhang, Samantha L. Kristufek and Jeremiah A. Johnson

Chem. Rev., 2021, 121, 7059
DOI: 10.1021/acs.chemrev.0c01282

Progress in the controllability technology of PROTAC

Xin He, Zhibing Weng and Yi Zou

European Journal of Medicinal Chemistry, 2024, 265, 116096
DOI: 10.1016/j.ejmech.2023.116096

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, Jing Yang and Chongge You

Molecules, 2023, 28, 4014
DOI: 10.3390/molecules28104014

Advancing Design Strategy of PROTACs for Cancer Therapy

Hang Luo, Yuan Tian, Razack Abdullah, Baoting Zhang, Yuan Ma and Ge Zhang

MedComm, 2025, 6
DOI: 10.1002/mco2.70258

PROTAC technology for prostate cancer treatment

Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka and Wenyi Wei

Acta Materia Medica, 2025, 4
DOI: 10.15212/AMM-2024-0075

Photomodulation Approaches to Overcome Antimicrobial Resistance

Sofia N. Sarabando, Andreia Palmeira, Maria Emília Sousa, Maria Amparo F. Faustino and Carlos J. P. Monteiro

Pharmaceuticals, 2023, 16, 682
DOI: 10.3390/ph16050682

Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands

Weiyan Cheng, Shasha Li, Siyuan Han, Ruoyang Miao, Suhua Wang, Chunxia Liu, Han Wei, Xin Tian and Xiaojian Zhang

Bioorganic & Medicinal Chemistry, 2023, 82, 117237
DOI: 10.1016/j.bmc.2023.117237

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points

Aleša Bricelj, Christian Steinebach, Robert Kuchta, Michael Gütschow and Izidor Sosič

Front. Chem., 2021, 9
DOI: 10.3389/fchem.2021.707317

Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis

Xiaoyan Lu, Xiaoning Wang, Hanwen Liao, Baitong Sha, Yan Zhang and Jinbo Li

Angew Chem Int Ed, 2025
DOI: 10.1002/anie.202510641

Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions

Akash Vikal, Rashmi Maurya, Brij Bihari Patel, Rajeev Sharma, Preeti Patel, Umesh K. Patil and Balak Das Kurmi

Drug Deliv. and Transl. Res., 2025, 15, 1801
DOI: 10.1007/s13346-024-01754-z

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Yufeng Xiao, Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou and Dongwen Lv

J. Med. Chem., 2024, 67, 11580
DOI: 10.1021/acs.jmedchem.4c00723

Current strategies for improving limitations of proteolysis targeting chimeras

Chunlan Pu, Shirui Wang, Lei Liu, Zhonghui Feng, Hongjia Zhang, Qianyuan Gong, Yueshan Sun, Yuanbiao Guo and Rui Li

Chinese Chemical Letters, 2023, 34, 107927
DOI: 10.1016/j.cclet.2022.107927

Chuhui Huang, Kate S. Harris, Ghizal Siddiqui and Manuela Jörg

ACS Pharmacol. Transl. Sci., 2025, 8, 978
DOI: 10.1021/acsptsci.4c00726

Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy

Soumik De, Raghaba Sahu, Shubhendu Palei and Laxmi Narayan Nanda

Bioorganic & Medicinal Chemistry, 2024, 112, 117875
DOI: 10.1016/j.bmc.2024.117875

Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability

Cyrille S. Kounde and Edward W. Tate

J. Med. Chem., 2020, 63, 15483
DOI: 10.1021/acs.jmedchem.0c01542

Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation

Yuhui Jin, Jing Fan, Ruyan Wang, Xuanyu Wang, Ning Li, Qidong You and Zhengyu Jiang

J. Am. Chem. Soc., 2023, 145, 7218
DOI: 10.1021/jacs.2c12809

Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues

Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv and Xiaodong Ma

J. Med. Chem., 2023, 66, 10122
DOI: 10.1021/acs.jmedchem.3c00079

Strategies for designing proteolysis targeting chimaeras (PROTACs)

Shipeng He, Guoqiang Dong, Junfei Cheng, Ying Wu and Chunquan Sheng

Medicinal Research Reviews, 2022, 42, 1280
DOI: 10.1002/med.21877

Hydrogen Peroxide‐Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

Dehao Yu, Heli Fan, Zhili Zhou, Ying Zhang, Jing Sun, Luo Wang, Yuanyuan Jia, Junyu Tian, Anahit Campbell, Wenyi Mi and Huabing Sun

ChemBioChem, 2023, 24
DOI: 10.1002/cbic.202300422

Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders

Nisha Setia, Haider Thaer Abdulhameed Almuqdadi and Mohammad Abid

European Journal of Medicinal Chemistry, 2024, 265, 116041
DOI: 10.1016/j.ejmech.2023.116041

A comprehensive review of BET-targeting PROTACs for cancer therapy

Xiao-Li Zhou, Fang Zhao, Yong-Tao Xu, Yuan-Yuan Guan, Tong Yu, Yi-Zhe Zhang, Ying-Chao Duan and Yuan Zhao

Bioorganic & Medicinal Chemistry, 2022, 73, 117033
DOI: 10.1016/j.bmc.2022.117033

Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC)

Zhenzhen Li, Siyue Ma, Xingye Yang, Ling Zhang, Dong Liang, Gaopan Dong, Lupei Du, Zhenghua Lv and Minyong Li

European Journal of Medicinal Chemistry, 2021, 222, 113608
DOI: 10.1016/j.ejmech.2021.113608

Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis

Xiaoyan Lu, Xiaoning Wang, Hanwen Liao, Baitong Sha, Yan Zhang and Jinbo Li

Angewandte Chemie, 2025
DOI: 10.1002/ange.202510641

Photoswitchable PROTACs for Reversible and Spatiotemporal Regulation of NAMPT and NAD+

Junfei Cheng, Jing Zhang, Shipeng He, Minyong Li, Guoqiang Dong and Chunquan Sheng

Angewandte Chemie, 2024, 136
DOI: 10.1002/ange.202315997

Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader

Linghao Hu, Huiyun Li, Junlin Qin, Dan Yang, Jieming Liu, Xiaomin Luo, Jingkun Ma, Cheng Luo, Fei Ye, Yubo Zhou, Jia Li and Mingliang Wang

J. Med. Chem., 2023, 66, 15269
DOI: 10.1021/acs.jmedchem.3c01348

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, Liyan cheng, Zhimin Zhang, Jian Wang and Zhengrong Shen

European Journal of Medicinal Chemistry, 2021, 210, 112981
DOI: 10.1016/j.ejmech.2020.112981

POT, an optogenetics-based endogenous protein degradation system

Yunyue Chen, Siyifei Wang, Luhao Zhang, Dandan Peng, Ke Huang, Baohua Ji, Junfen Fu and Yingke Xu

Commun Biol, 2025, 8
DOI: 10.1038/s42003-025-07919-x

Photoswitchable PROTACs for Reversible and Spatiotemporal Regulation of NAMPT and NAD+

Junfei Cheng, Jing Zhang, Shipeng He, Minyong Li, Guoqiang Dong and Chunquan Sheng

Angew Chem Int Ed, 2024, 63
DOI: 10.1002/anie.202315997

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

Ming He, Chaoguo Cao, Zhihao Ni, Yongbo Liu, Peilu Song, Shuang Hao, Yuna He, Xiuyun Sun and Yu Rao

Sig Transduct Target Ther, 2022, 7
DOI: 10.1038/s41392-022-00999-9

Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras

Chunlong Zhao and Frank J. Dekker

ACS Pharmacol. Transl. Sci., 2022, 5, 710
DOI: 10.1021/acsptsci.2c00089

Major Advances in Emerging Degrader Technologies

Hang Luo, Li Wu, Yujian He, Chong Qin and Xinjing Tang

Front. Cell Dev. Biol., 2022, 10
DOI: 10.3389/fcell.2022.921958

Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues

Shi Shi, Yu Du, Yi Zou, Jing Niu, Zeyu Cai, Xiaonan Wang, Feihuang Qiu, Yi Ding, Gengchen Yang, Yunze Wu, Yungen Xu and Qihua Zhu

J. Med. Chem., 2022, 65, 5057
DOI: 10.1021/acs.jmedchem.1c02221

Targeted Protein Degradation through Fast Optogenetic Activation and Its Application to the Control of Cell Signaling

Amy Ryan, Jihe Liu and Alexander Deiters

J. Am. Chem. Soc., 2021, 143, 9222
DOI: 10.1021/jacs.1c04324

Hypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression

Guang Yang, Rachel Shi and Qing Zhang

IJMS, 2020, 21, 8162
DOI: 10.3390/ijms21218162

Bifunctional robots inducing targeted protein degradation

M Elizabeth Sobhia, Harish Kumar and Sonia Kumari

European Journal of Medicinal Chemistry, 2023, 255, 115384
DOI: 10.1016/j.ejmech.2023.115384

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

Chao Wang, Yujing Zhang, Jie Wang and Dongming Xing

European Journal of Medicinal Chemistry, 2022, 227, 113906
DOI: 10.1016/j.ejmech.2021.113906

Targeted Protein Degradation: Clinical Advances in the Field of Oncology

Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova and Iris Z. Uras

IJMS, 2022, 23, 15440
DOI: 10.3390/ijms232315440

PROTACs for BRDs proteins in cancer therapy: a review

Chao Wang, Yujing Zhang, Shanbo Yang, Wujun Chen and Dongming Xing

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1694
DOI: 10.1080/14756366.2022.2081164

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Jing Gao, Lei Yang, Shumin Lei, Feng Zhou, Huijun Nie, Bo Peng, Tianfeng Xu, Xiaohua Chen, Xiaobao Yang, Chunquan Sheng, Yu Rao, Kanyi Pu, Jian Jin, Zhiai Xu and Haijun Yu

Science Bulletin, 2023, 68, 1069
DOI: 10.1016/j.scib.2023.04.028

Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic

Zhenyi Hu and Craig M. Crews

ChemBioChem, 2022, 23
DOI: 10.1002/cbic.202100270

Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy

Fabian B. Kraft, Maria Hanl, Felix Feller, Linda Schäker-Hübner and Finn K. Hansen

Pharmaceuticals, 2023, 16, 356
DOI: 10.3390/ph16030356

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Rui Yao, Tianli Luo and Ming Wang

ChemBioChem, 2023, 24
DOI: 10.1002/cbic.202300413

Precise Modulation of Protein Degradation by Smart PROTACs

Junfei Cheng, Guoqiang Dong, Wei Wang and Chunquan Sheng

ChemBioChem, 2025, 26
DOI: 10.1002/cbic.202400682

Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer Targeting

Yanchi Chen, Lina Zhang, Lincheng Fang, Chengjie Chen, Dong Zhang and Tao Peng

JACS Au, 2024, 4, 2564
DOI: 10.1021/jacsau.4c00298

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents

Chao Wang, Yujing Zhang, Lingyu Shi, Shanbo Yang, Jing Chang, Yingjie Zhong, Qian Li and Dongming Xing

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1437
DOI: 10.1080/14756366.2022.2074414

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Jin Li, Xinxin Chen, Aiping Lu and Chao Liang

The Innovation, 2023, 4, 100413
DOI: 10.1016/j.xinn.2023.100413

Targeted protein degradation: A promise for undruggable proteins

Kusal T.G. Samarasinghe and Craig M. Crews

Cell Chemical Biology, 2021, 28, 934
DOI: 10.1016/j.chembiol.2021.04.011

Frontiers in PROTACs

Gregory R. Hughes, Ashley P. Dudey, Andrew M. Hemmings and Andrew Chantry

Drug Discovery Today, 2021, 26, 2377
DOI: 10.1016/j.drudis.2021.04.010

PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications

Narayanaperumal Pravin and Krzysztof Jóźwiak

European Journal of Medicinal Chemistry, 2024, 279, 116837
DOI: 10.1016/j.ejmech.2024.116837

Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer

Chao Wang, Han Wang, Cangxin Zheng, Zhenming Liu, Xiaozuo Gao, Fengrong Xu, Yan Niu, Liangren Zhang and Ping Xu

European Journal of Medicinal Chemistry, 2021, 218, 113386
DOI: 10.1016/j.ejmech.2021.113386

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation

Jing Liu, Yunhua Peng and Wenyi Wei

Front. Cell Dev. Biol., 2021, 9
DOI: 10.3389/fcell.2021.678077

Development of visible-light-activatable photocaged PROTACs

Weizhi Weng, Gang Xue and Zhengying Pan

European Journal of Medicinal Chemistry, 2024, 265, 116062
DOI: 10.1016/j.ejmech.2023.116062

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Xinyi Li, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen and Yong Peng

Mol Cancer, 2022, 21
DOI: 10.1186/s12943-021-01434-3

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Hong‐Yi Zhao, Minhang Xin and San‐Qi Zhang

Drug Development Research, 2023, 84, 337
DOI: 10.1002/ddr.22026

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity

Chuanjie Chen, Yiwen Yang, Zhe Wang, Huiwen Li, Chanjuan Dong and Xuan Zhang

J. Med. Chem., 2023, 66, 8428
DOI: 10.1021/acs.jmedchem.3c00302

Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One

Alessandra Salerno, Francesca Seghetti, Jessica Caciolla, Elisa Uliassi, Eleonora Testi, Melissa Guardigni, Marinella Roberti, Andrea Milelli and Maria Laura Bolognesi

J. Med. Chem., 2022, 65, 9507
DOI: 10.1021/acs.jmedchem.2c00302

PROTAC delivery in tumor immunotherapy: Where are we and where are we going?

Yiyang Li, Yike Wu, Sihan Gao, Tao Sun and Chen Jiang

Journal of Controlled Release, 2025, 378, 116
DOI: 10.1016/j.jconrel.2024.11.076

Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development

Moyang Lv, Weichao Hu, Shengwei Zhang, Lijiao He, Changjiang Hu and Shiming Yang

Cancer Letters, 2022, 539, 215716
DOI: 10.1016/j.canlet.2022.215716

Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy

Weishan Wang, Chenghong Zhu, Bin Zhang, Yi Feng, Yan Zhang and Jinbo Li

J. Am. Chem. Soc., 2023, 145, 16642
DOI: 10.1021/jacs.3c04109